Tivozanib Maintains PFS Benefit VS Sorafenib in R/R Renal Cell Carcinoma
November 6th 2022Results presented at the 2022 International Kidney Cancer Symposium show tivozanib continues to demonstrate progression-free survival benefit over sorafenib in relapsed or refractory renal cell carcinoma.
Read More
Lenvatinib/Pembrolizumab Upholds Efficacy Vs Sunitinib in Frontline Advanced RCC Vs Sunitinib
November 6th 2022After approximately 33 months of extended follow-up in the CLEAR study, investigators say lenvatinib plus pembrolizumab should be considered a standard of care option for frontline advanced renal cell carcinoma.
Read More
Need for Subsequent Therapy Limited With Lenvatinib/Pembrolizumab in Advanced RCC
November 5th 2022Subsequent therapy rates were lower in patients with advanced renal cell carcinoma treated with the combination of lenvatinib and pembrolizumab vs those who received sunitinib in the CLEAR trial.
Read More
Nivolumab Plus Ipilimumab Prolongs Survival in Treatment-Naïve Advanced Sarcomatoid RCC
November 5th 2022Post hoc CheckMate 214 results show that nivolumab plus ipilimumab extend progression and overall survival in patient with advanced sarcomatoid renal cell carcinoma who have not be previously treated.
Read More
Doctors Debate: Should Upfront Therapy for RCC Consist of Doublets or Triplets?
November 4th 2022During a debate at the 2022 International Kidney Cancer Symposium, Yousef Zakharia, MD and Rana M. McKay, MD presented argument for the use of doublets or triplets in patients with renal cell carcinoma.canc
Read More
Efficacy and Safety Assessment of Frontline Lenvatinib Plus Pembrolizumab Underway for nccRCC
November 6th 2021The frontline combination of lenvatinib and pembrolizumab is under investigation as a treatment option for patients with non-clear cell renal cell carcinoma in the recently launched phase 2 KEYNOTE-B61 trial.
Read More
Precision Medicine According to Histologic Subtype in Renal Cell Carcinoma
November 6th 2021During a presentation at the 2021 International Kidney Cancer Symposium, Bradley McGregor, MD, discussed analyses of outcomes based on histology in major RCC clinical trials, and how this approach will shape the future of treatment.
Read More
Kaelin Speaks to the Future of I/O, HIF-2α, CDK4/6 Inhibitors in VHL Disease–Associated RCC
November 7th 2020During a keynote address for the International Kidney Cancer Symposium, William G. Kaelin Jr, MD, spoke of recent research on effective treatment with the ability to target von Hippel-Lindau disease–associated renal cell carcinoma. These drugs included immunotherapy, HIF-2α inhibitors, and CDK4/6 inhibitors, which may be the future of the treatment paradigm.
Read More
Safety, Tolerability Profile for Low-Dose Lenvatinib Is Similar to Standard Dose in RCC
November 7th 2020Findings from a phase 2 trial evaluating lenvatinib given at 2 different starting doses, 14 mg versus 18 mg, in combination with everolimus, suggest the lower dose is similar to the standard dose in terms of efficacy and safety with minimal differences observed between the 2 arms.
Read More
Cost-Effective Option Best for Frontline Immunotherapy/TKI Combination in RCC
November 7th 2020Significant overall survival and progression-free survival benefits were observed with combination regimens containing immunotherapy in combination with a tyrosine kinase inhibitor, along with tolerable safety in patients with renal cell carcinoma to Suzanne Cole, MD, FACP noted, however, that the cost of these combination can dim the light on the advantages.
Read More
Lenvatinib Plus Pembrolizumab Demonstrates Antitumor Activity in Metastatic ccRCC
November 7th 2020In patients with metastatic clear cell renal cell carcinoma who had progressed on prior PD-1 or PD-L1 immune checkpoint inhibitor therapy, the combination of lenvatinib and pembrolizumab achieved antitumor responses, according to results from a phase 2 trial.
Read More
Cabozantinib Leading the Emerging Therapies in Advanced RCC
November 6th 2020In an interview with Targeted Oncology, Toni K. Choueiri, MD, discussed key results from the CheckMate-9ER trial in advanced renal cell carcinoma, as well as ongoing trials with the potential to move the landscape further along.
Read More
Lenvatinib Combo Shows Promising Findings in Phase 2 Study of Non-Clear Cell Renal Cell Carcinoma
November 6th 2020Lenvatinib plus everolimus demonstrated anti-tumor activity as treatment of patients with advanced non-clear cell renal cell carcinoma in the frontline setting, according to findings from a phase 2 clinical trial.
Read More
Lenvatinib/Pembrolizumab Combo Demonstrates Strong Antitumor Activity in Metastatic RCC
November 17th 2019Findings from a planned interim analysis of the Ib/II Study 111 showed that lenvatinib plus pembrolizumab induced a disease control rate of 94% in patients with metastatic clear cell RCC who had disease progression following treatment with a PD-1/PD-L1 inhibitor.
Read More
Discussing the Phase II Study of Lenvatinib/Pembrolizumab in Metastatic ccRCC
November 17th 2019Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the rationale for the phase II study of lenvatinib plus pembrolizumab for disease progression after PD-1/PD-L1 immune checkpoint inhibitor in metastatic clear cell renal cell carcinoma.<br />
Read More
Nivolumab/Ipilimumab Combo Extends Treatment-Free Survival in RCC
November 17th 2019Patients with advanced renal cell carcinoma assigned to nivolumab plus ipilimumab had a longer treatment-free survival than patients treated with sunitinib. Furthermore, those patients assigned to the combination spent less time experiencing treatment-related adverse events.
Read More
Deciding on the Ideal First-Line Treatment for Rare and Advanced Kidney Cancers
November 16th 2019In an interview with Targeted Oncology at the IKCS meeting, Gennady Bratslavsky, MD, provided his expert opinion on the optimal first-line therapy for non–clear cell renal cell carcinoma, a topic he debated on with peers at the 2019 International Kidney Cancer Symposium.
Read More
Exploring MEDI0680/Durvalumab Versus Nivolumab in Metastatic ccRCC
November 16th 2019Martin H. Voss, reviews the method of design and results for the phase I/II study of the experimental anti–PD-1 anitbody MEDI0680 plus durvalumab versus nivolumab monotherapy in patients with metastatic clear cell renal cell carcinoma.<br />
Read More
Managing GI Toxicities Associated With Immune Checkpoint Inhibition in Kidney Cancer
November 16th 2019In an interview with Targeted Oncology during the 2019 International Kidney Cancer Symposium, Yinghong Wang, MD, PhD, MS, discussed the management of gi-related toxicity in patients with kidney cancer from the perspective of a gastrointestinal specialist. She also explained the multidisciplinary collaboration between oncology and gastrointestinal departments to enhance care.
Read More